
|
Dendreon Corporation. The Company's principal activities are to discover and develop novel products for the treatment of diseases through innovative manipulation of the immune system. It's product pipeline is focused on treatment of cancer and includes therapeutic vaccines, monoclonal antibodies, small molecules and pro-drugs. It's product Provenge, ... More
|
|
|
|
First Call expects -0.29 EPS for next quarter.
The current Price Target for DNDN is $34.13.

| 27.54 Last |
Today’s Change |
28.30 Today’s Open |
$28.39 Day High |
$27.31 Day Low |
-- Volume |
| Quotes delayed by at least 20 minutes | |||||
DNDN
IndustryMouse over chart for more details